Published in Clin Cancer Res on May 15, 2015
A Phase 1/2 Study to Evaluate MEDI4736 | NCT01693562
A Study of LY2940680 in Small Cell Lung Cancer | NCT01722292
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer | NCT01441297
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03
Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol (2016) 0.97
Lung cancer in the era of precision medicine. Clin Cancer Res (2015) 0.96
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res (2015) 0.84
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC? J Thorac Oncol (2016) 0.78
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Rep (2016) 0.78
Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. Oxid Med Cell Longev (2016) 0.78
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res (2016) 0.78
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. PLoS Genet (2016) 0.77
Smoking, inflammation and small cell lung cancer: recent developments. Wien Med Wochenschr (2015) 0.77
EMT influences the expression of CK19 in pleural effusion-derived lung cancer cells and their invasion and metastasis. Oncol Lett (2016) 0.75
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell (2016) 0.75
Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. Lung (2017) 0.75
Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 0.75
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Curr Oncol Rep (2017) 0.75
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
The epigenomics of cancer. Cell (2007) 30.91
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Applying the principles of stem-cell biology to cancer. Nat Rev Cancer (2003) 8.95
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell (2003) 3.31
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol (2006) 2.91
The Aurora kinase family in cell division and cancer. Biochim Biophys Acta (2008) 2.84
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 2.63
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2009) 2.58
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov (2013) 2.46
Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol (2002) 2.40
A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell (2011) 2.29
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med (2014) 2.12
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97
Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol (2005) 1.96
Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 1.96
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol (2015) 1.85
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer (2015) 1.85
Histone acetylation and chromatin remodeling. Exp Cell Res (2001) 1.85
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell (2013) 1.85
Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res (2010) 1.81
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol (2007) 1.79
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer (2005) 1.73
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol (2007) 1.67
Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol (2009) 1.66
Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene (1990) 1.63
Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.62
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res (2015) 1.61
Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol (2014) 1.60
Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differ (1997) 1.57
Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res (2009) 1.55
DNA methylation profiles of lung tumors. Mol Cancer Ther (2001) 1.53
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol (2008) 1.51
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene (2004) 1.49
ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res (2005) 1.45
The solitary pulmonary nodule. Ten-year follow-up of veterans administration-armed forces cooperative study. Arch Surg (1975) 1.42
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol (2008) 1.41
Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol (2006) 1.39
Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.39
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol (2006) 1.39
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol (2004) 1.37
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol (2010) 1.29
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol (2009) 1.27
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol (2011) 1.23
Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. PLoS Med (2006) 1.21
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res (2010) 1.20
Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev (2005) 1.17
Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem (2008) 1.17
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A (2014) 1.17
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol (2005) 1.15
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res (2004) 1.13
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer (2011) 1.10
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther (2009) 1.10
Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res (2008) 1.09
Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) (2012) 1.08
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol (2010) 1.07
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther (2012) 1.04
PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res (2014) 1.02
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res (2015) 1.02
Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol (1999) 1.01
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol (2009) 1.00
Genetic changes in small cell lung carcinoma. Clin Transl Oncol (2008) 1.00
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol (2011) 0.99
Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer (2012) 0.98
Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res (2015) 0.97